DNLI logo

Denali Therapeutics (DNLI) Company Overview

Profile

Full Name:

Denali Therapeutics Inc.

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

December 8, 2017

Indexes:

Not included

Website:

http://www.denalitherapeutics.com

Description:

Denali Therapeutics Inc. specializes in developing methods for treating patients with neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), and others. Denali Therapeutics was registered in 2013, with its headquarters located in South San Francisco, California. In the Company's diversified portfolio, drug development is based on scientific understanding of the genetic causes and biological processes underlying neurodegenerative diseases. The company is conducting research programs on the Lysosomal Function Pathway, Glial Nature Pathway, and Cellular Homeostasis Pathway. Its candidate drugs include DNL201, DNL 151, ATV:aSyn, ETV:IDS, DNL747, and ATV:TREM2.

Key Details

Price

$16.80

Market Cap

$2.44 B(Mid cap)

Last Dividend

-

TTM Dividend Yield

-

Annual Revenue

-

Annual EPS

-$2.57(-142.45% YoY)

PE Ratio

-

Annual ROE

-34.38%

Annual Debt To Equity

0.04

Beta

1.71

Events Calendar

Earnings

Next earnings date:

N/A

Recent quarterly earnings:

Feb 27, 2025

Recent annual earnings:

Feb 27, 2025
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

Mar 5, 25 B. Riley Securities
Buy
Mar 3, 25 Oppenheimer
Outperform
Feb 28, 25 HC Wainwright & Co.
Buy
Feb 11, 25 Deutsche Bank
Buy
Jan 28, 25 Goldman Sachs
Buy
Jan 7, 25 JP Morgan
Overweight
Jan 7, 25 HC Wainwright & Co.
Buy
Jan 7, 25 Baird
Outperform
Jan 3, 25 William Blair
Outperform
Dec 16, 24 Stifel
Buy

Screeners with DNLI included

Growing Shares Outstanding
Mid cap stocks
US stocks
Stocks with high beta
Most recommended stocks
Stocks below analysts price target
Healthcare sector
All stocks
Biotechnology industry
NASDAQ earnings calendar

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Current Price

$16.80
DNLI price is $16.80

Price All-time High

$93.56
DNLI price is currently -82.04% below its historical high of $93.56

Price Analysts Target

$33.50
DNLI price is currently -49.85% lower than the consensus analysts' forecast

Price Most Recent Change

+2.75%
DNLI price was up +2.75% on Mar 7, 2025

Price YTD Change

-17.57%
DNLI price is down -17.57% since January 1st

Price 3-Year Change

-45.65%
DNLI price is down -45.65% over the past 3 years

Market cap

Market Cap

$2.44 B
DNLI market capitalization is $2.44 billion

Market Cap 3-Year Change

-35.75%
DNLI market capitalization is down -35.75% over the past 3 years

Market Cap All-time High

$11.22 B
DNLI market capitalization is currently -78.26% below its historical high of $11.22 billion

Market Cap Sector Rank

83.79%
DNLI market capitalization is higher than 83.79% of companies in Healthcare sector

Technical

Beta

1.71
DNLI beta is 1.71

200-day SMA

$23.61
DNLI price is currently -28.85% below its 200-day simple moving average

14-day RSI

33.75
DNLI 14-day relative strength index is 33.75

30-day Relative Volume

1.52
DNLI 30-day relative volume is 1.52

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Annual Revenue

-
DNLI annual revenue value is unknown

Annual Revenue Analysts Estimate

$20.62 M
DNLI annual revenue is currently equal to the consensus analysts' forecast

Annual Revenue 1-Year Change

-
DNLI annual revenue 1-year change is unknown

Annual Revenue Sector Rank

-
DNLI annual revenue is unknown

Profit

Annual Gross Profit

-
DNLI annual gross profit value is unknown

Annual Gross Margin

-
DNLI annual gross profit margin value is unknown

Annual Operating Profit

-$501.88 M
DNLI annual operating income is -$501.88 million

Annual Operating Margin

-
DNLI annual operating profit margin value is unknown

Annual Net Income

-$422.77 M
DNLI annual net profit is -$422.77 million

Annual Net Margin

-
DNLI annual net profit margin value is unknown

EPS

Annual EPS

-$2.57
DNLI annual earnings per share is -$2.57

Annual EPS Analysts Estimate

-$2.86
DNLI annual earnings per share is currently -10.11% lower than the consensus analysts' forecast

Annual EPS 1-Year Change

-142.45%
DNLI annual earnings per share is down -142.45% year-on-year

Annual EPS Sector Rank

36.82%
DNLI annual earnings per share is higher than 36.82% of companies in Healthcare sector

ROA & ROE

Annual ROA

-30.77%
DNLI annual return on assets is -30.77%

Annual ROE

-34.38%
DNLI annual return on equity is -34.38%

EBIT & EBITDA

Annual EBIT

-$501.88 M
DNLI annual earnings before interest & taxes is -$501.88 million

Annual EBITDA

-$492.89 M
DNLI annual EBITDA is -$492.89 million

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PE Ratio

-
DNLI price to earnings ratio value is unknown

PE Ratio Sector Rank

-
DNLI price to earnings ratio is unknown

PB Ratio

PB Ratio

1.98
DNLI price to book ratio is 1.98

PB Ratio Sector Rank

59.08%
DNLI price to book ratio is higher than 59.08% of companies in Healthcare sector

PS Ratio

PS Ratio

-
DNLI price to sales ratio value is unknown

PS Ratio Sector Rank

-
DNLI price to sales ratio is unknown

Enterprise value

Enterprise Value

$2.31 B
DNLI enterprise value is $2.31 billion

Enterprise Value Sector Rank

82.89%
DNLI enterprise value is higher than 82.89% of companies in Healthcare sector

EV/EBITDA

EV/EBITDA

-4.69
DNLI EV/EBITDA is -4.69

EV/EBITDA Sector Rank

22.52%
DNLI EV/EBITDA is higher than 22.52% of companies in Healthcare sector

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Annual Current Ratio

8.46
DNLI annual current ratio is 8.46

Annual Quick Ratio

-
DNLI annual quick ratio value is unknown

Leverage

Annual Debt To Equity

0.04
DNLI annual debt to equity ratio is 0.04

Annual Interest Coverage Ratio

-
DNLI annual interest coverage ratio value is unknown

Risk & Stability

Piotroski F-Score

-
DNLI piotroski f-score value is unknown

Altman Z-Score

-
DNLI altman z-score value is unknown

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Annual Total Assets

$1.37 B
DNLI annual total assets is $1.37 billion

Annual Non Current Assets

$509.74 M
DNLI annual long term assets is $509.74 million

Annual Current Assets

$864.44 M
DNLI annual total current assets is $864.44 million

Annual Cash & Cash Equivalents

$174.96 M
DNLI annual cash & cash equivalents is $174.96 million

Equity

Annual Book Value

$1.23 B
DNLI annual book value is $1.23 billion

Annual Working Capital

$762.23 M
DNLI annual working capital is $762.23 million

Liabilities

Annual Total Liabilities

$144.50 M
DNLI annual total liabilities is $144.50 million

Annual Total Long Term Liabilities

$42.29 M
DNLI annual total long term liabilities is $42.29 million

Annual Current Liabilities

$102.21 M
DNLI annual total current liabilities is $102.21 million

Annual Accounts Payable

$11.14 M
DNLI annual accounts payable is $11.14 million

Debt

Annual Total Debt

$48.71 M
DNLI annual total debt is $48.71 million

Annual Total Debt 1-Year Change

-6.76%
DNLI annual total debt is down -6.76% year-on-year

Annual Long Term Debt

$36.67 M
DNLI annual long term debt is $36.67 million

Annual Short Term Debt

$12.03 M
DNLI annual short term debt is $12.03 million

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Annual Total Expenses

$501.88 M
DNLI annual total expenses is $501.88 million

Annual Operating Expenses

$501.88 M
DNLI annual total operating expenses is $501.88 million

Annual Cost Of Goods Sold

-
DNLI annual cost of goods sold value is unknown

Annual SGA

$105.44 M
DNLI annual SGA is $105.44 million

Annual D&A

$8.99 M
DNLI annual depreciation & amortization is $8.99 million

Annual Interest Expense

-
DNLI annual interest expense value is unknown

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Annual CFO

-$347.69 M
DNLI annual cash flow from operations is -$347.69 million

Annual CFO 1-Year Change

+2.88%
DNLI annual cash flow from operations is up +2.88% year-on-year

Annual CFI

-$88.76 M
DNLI annual cash flow from investing activities is -$88.76 million

Annual CFI 1-Year Change

-135.6%
DNLI annual cash flow from investing activities is down -135.6% year-on-year

Annual CFF

$484.30 M
DNLI annual cash flow from financing activities is $484.30 million

Annual CFF 1-Year Change

+2617.76%
DNLI annual cash flow from financing activities is up +2617.76% year-on-year

Free CashFlow

Annual FCF

-$363.61 M
DNLI annual free cash flow is -$363.61 million

Annual FCF 1-Year Change

+1.97%
DNLI annual free cash flow is up +1.97% year-on-year

CAPEX

Annual CAPEX

-
DNLI annual capital expenditures value is unknown

Annual CAPEX 1-Year Change

-
DNLI annual capital expenditures 1-year change is unknown

Institutional Ownership

Similar stocks

MLTX logo
MoonLake Immunotherapeutics (MLTX)
VCEL logo
Vericel (VCEL)
VCYT logo
Veracyte (VCYT)
BEAM logo
Beam Therapeutics (BEAM)
WRBY logo
Warby Parker (WRBY)
SEM logo
Select Medical Holdings (SEM)
PTGX logo
Protagonist Therapeutics (PTGX)
TWST logo
Twist Bioscience (TWST)
NAMS logo
NewAmsterdam Pharma Company NV (NAMS)

FAQ

  • What is the ticker symbol for Denali Therapeutics?
  • Does Denali Therapeutics pay dividends?
  • What sector is Denali Therapeutics in?
  • What industry is Denali Therapeutics in?
  • What country is Denali Therapeutics based in?
  • When did Denali Therapeutics go public?
  • Is Denali Therapeutics in the S&P 500?
  • Is Denali Therapeutics in the NASDAQ 100?
  • Is Denali Therapeutics in the Dow Jones?
  • When was Denali Therapeutics's last earnings report?
  • When does Denali Therapeutics report earnings?
  • Should I buy Denali Therapeutics stock now?

What is the ticker symbol for Denali Therapeutics?

The ticker symbol for Denali Therapeutics is NASDAQ:DNLI

Does Denali Therapeutics pay dividends?

No, Denali Therapeutics does not pay dividends

What sector is Denali Therapeutics in?

Denali Therapeutics is in the Healthcare sector

What industry is Denali Therapeutics in?

Denali Therapeutics is in the Biotechnology industry

What country is Denali Therapeutics based in?

Denali Therapeutics is headquartered in United States

When did Denali Therapeutics go public?

Denali Therapeutics's initial public offering (IPO) was on December 8, 2017

Is Denali Therapeutics in the S&P 500?

No, Denali Therapeutics is not included in the S&P 500 index

Is Denali Therapeutics in the NASDAQ 100?

No, Denali Therapeutics is not included in the NASDAQ 100 index

Is Denali Therapeutics in the Dow Jones?

No, Denali Therapeutics is not included in the Dow Jones index

When was Denali Therapeutics's last earnings report?

Denali Therapeutics's most recent earnings report was on Feb 27, 2025

When does Denali Therapeutics report earnings?

The date for Denali Therapeutics's next earnings report has not been announced yet

Should I buy Denali Therapeutics stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions